Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Epuris Sales in Mexico

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Nov 23, 2021 7:07pm

148 Views

Post# 34159398

RE:RE:Epuris Sales in Mexico

Brazil is the second largest isotrention in market in the world.
Brazil dominated the Latin America acne medication market and was valued at over USD 110.9 million in the year 2017.

I don't know what it is now but probably much larger.

Brazil has a population of 220 m and Mexico 130 m .
Both have significant youth in their population statistics.

So, based on this, I think that Italmex will have significant sales success in Mexico

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter